XML 25 R6.htm IDEA: XBRL DOCUMENT v3.4.0.3
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Mar. 31, 2014
Operating Activities      
Net income $ 99,907 $ 78,260 $ 72,615
Adjustments to reconcile net income to net cash provided by (used in) operating activities:      
Depreciation and amortization 23,676 17,740 13,486
Gain on sale of asset 0 (1,133) 0
Deferred income taxes 46,152 28,922 19,012
Long term income taxes payable (332) 2,294 0
Amortization of debt origination costs 8,994 8,821 10,512
Stock-based compensation costs 9,954 6,918 5,146
Loss on extinguishment of debt 17,970 0 18,286
Premium payment on Senior Notes     (15,527)
Lease termination costs 0 785 0
(Gain) loss on sale or disposal of property and equipment (35) 321 (3)
Changes in operating assets and liabilities, net of effects from acquisitions      
Accounts receivable 1,824 1,608 9,735
Inventories (3,005) 15,360 (2,850)
Prepaid expenses and other current assets (7,921) 4,664 (2,130)
Accounts payable (11,348) (17,637) (4,641)
Accrued liabilities (1,328) 9,332 (12,059)
Net cash provided by operating activities 174,350 156,255 111,582
Investing Activities      
Purchases of property and equipment (3,568) (6,101) (2,764)
Proceeds from the sale of property and equipment 344 0 3
Proceeds from sale of business 0 18,500 0
Proceeds from sale of asset 0 10,000 0
Proceeds from Insight Pharmaceuticals working capital arbitration settlement 7,237 0 0
Net cash used in investing activities (222,971) (805,258) (57,976)
Financing Activities      
Borrowings under Bridge term loans 80,000 0 0
Repayments under Bridge term loans (80,000) 0 0
Term loan borrowings 0 720,000 0
Term loan repayments (60,000) (130,000) (157,500)
Borrowings under revolving credit agreement 115,000 124,600 50,000
Repayments under revolving credit agreement (96,100) (58,500) (83,000)
Payments of debt origination costs (11,828) (16,072) (7,466)
Proceeds from exercise of stock options 6,689 3,954 5,907
Proceeds from restricted stock exercises 544 57 0
Excess tax benefits from share-based awards 1,960 1,330 1,650
Fair value of shares surrendered as payment of tax withholding (2,229) (2,104) (744)
Net cash (used in) provided by financing activities 54,036 643,265 (41,153)
Effects of exchange rate changes on cash and cash equivalents 497 (1,275) 208
Increase (decrease) in cash and cash equivalents 5,912 (7,013) 12,661
Cash and cash equivalents - beginning of year 21,318 28,331 15,670
Cash and cash equivalents - end of year 27,230 21,318 28,331
Interest paid 79,132 70,155 62,357
Income taxes paid 15,352 11,939 11,020
DenTek Oral Care, Inc.      
Investing Activities      
Acquisitions, less cash acquired (226,984) 0 0
Insight Pharmaceuticals      
Investing Activities      
Proceeds from Insight Pharmaceuticals working capital arbitration settlement 7,237    
Acquisitions, less cash acquired 0 (749,666) 0
Hydralyte      
Investing Activities      
Acquisitions, less cash acquired 0 (77,991) 0
Care Pharma      
Investing Activities      
Acquisitions, less cash acquired 0 0 (55,215)
2012 Senior Notes      
Adjustments to reconcile net income to net cash provided by (used in) operating activities:      
Premium payment on Senior Notes (10,158) 0 0
Financing Activities      
Repayment of Senior Notes (250,000) 0 0
2010 Senior Notes      
Adjustments to reconcile net income to net cash provided by (used in) operating activities:      
Premium payment on Senior Notes 0 0 (15,527)
Financing Activities      
Repayment of Senior Notes 0 0 (250,000)
2016 Senior Notes      
Financing Activities      
Proceeds from issuance of Senior Notes 350,000 0 0
2013 Senior Notes      
Financing Activities      
Proceeds from issuance of Senior Notes $ 0 $ 0 $ 400,000